

Asia COVID-19 & Vaccine Tracker

Ready for a holiday?

- ASEAN is starting to open up its borders to mass tourism, with Singapore taking the lead in October, Thailand in November
- Indonesia has opened Bali and Riau islands from 14 October, while Vietnam is set to open key tourist spots in December
- Despite low vaccination rates nationwide, some authorities are accelerating vaccinations in tourism-reliant regions

See you at the beach

Suitcases are being dusted off this week, as a handful of ASEAN countries have announced concrete plans to re-open borders for *fully* vaccinated international travellers. From 19 October, Singapore will welcome tourists from eight countries, including the US, Canada and six European countries, without quarantine under the Vaccinated Travel Lane (VTL) scheme. This will also be extended to South Korea from 15 November. This is not Singapore's first re-opening. In fact, it has set up an Air Travel Pass (ATP) with Greater China since as early as November 2020, before piloting its VTL with Germany and Brunei this September.

Meanwhile, Thailand has also continued to push its ambitious plans. After its pilot programs in Phuket and other popular islands, Thailand will open the *entire* country to tourists from at least 10 low-risk countries, including Singapore, mainland China, Germany and the US, from 1 November. The program will be extended to more countries from 1 December, by which time Thailand will also consider lifting restrictions on the operation of entertainment venues and on alcohol consumption in restaurants. Elsewhere in ASEAN, countries are also opening at least partially some key tourist destinations. Indonesia's Bali and Riau islands have kick-started their openings to travellers from 18 countries from 14 October. However, visitors are still required to undergo a 5-day quarantine. Malaysia is looking to re-open borders in December, while Vietnam is eyeing to allow some foreign travellers to its popular destinations, such as Halong Bay and Hoi An, in December.

Targeted vaccination

But one caveat is the low vaccination rate in ASEAN, except Singapore (80%+) and Malaysia (c60%). While many economies have ramped up their vaccination pace, more progress needs to be made, with full vaccination rates only reaching 33% in Thailand, 21% in Indonesia and the Philippines, and 16% in Vietnam (Chart 2). That said, authorities are prioritizing vaccination in key tourist destinations. This is not new. Just days before the Phuket sandbox scheme was introduced on 1 July, around 63% of its residents were fully vaccinated (*Bangkok Post*, 30 June). Since then, others have also followed suit. For example, despite Indonesia's relatively low national inoculation rate, Bali island has vaccinated over 80% of its population (*Straits Times*, 12 October). Similarly, Vietnam's Quang Ninh province, where Halong Bay is located, has fully inoculated almost 50% of its population, according to statistics published in *VNExpress*.

This is an abridged version of a report by the same title published on 15-Oct-21. Please contact your HSBC representative or email <u>AskResearch@hsbc.com</u> for more information.

Disclosures & Disclaimer

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

Free to View Economics - Asia

Yun Liu

Economist The Hongkong and Shanghai Banking Corporation Limited

Frederic Neumann

Co-Head of Asian Economics Research The Hongkong and Shanghai Banking Corporation Limited

Heidi Tang

Associate, Economics Research The Hongkong and Shanghai Banking Corporation Limited

Issuer of report: The Hongkong and Shanghai Banking Corporation Limited

View HSBC Global Research at:

https://www.research.hsbc.com



Asia COVID-19 and Vaccine Tracker

Chart 1: Total confirmed vaccine doses by country and territory (% of population)

Most economies have secured enough vaccine doses to vaccinate at least 50% of their population



Source: CH – mainland China. Duke University's data do not include domestic supply for mainland China (not made publicly available). Source: Duke University Health Innovation Center, HSBC

Chart 2: Percentage of people who received at least one dose and were fully vaccinated



Note: *CH – mainland China data is our estimates, as of 28 September, 72.56% of the population is fully vaccinated. Source: Our World in Data, HSBC



Chart 3: Cumulative confirmed COVID-19 cases per one million population

Note: *CH – mainland China Source: CEIC, HSBC

Mainland China and Singapore lead Asia in terms of vaccination progress

Number of confirmed COVID-

19 cases (per one million people) in Asia remains far

below those in Western

economies



Vaccination rates in India and

Vietnam have picked up in

the past week



Asia COVID-19 and Vaccine Tracker

Chart 4: Daily vaccination rate per economy (7-day moving average)

Source: Our World in Data, HSBC. Note: *CH - mainland China.



New Zealand and Vietnam are leading in terms of daily doses per million population



Source: Our World in Data, HSBC. Note: *CH - mainland China.





At current daily vaccination rate, when might 70% of the population be fully vaccinated?

Source: Our World in Data, HSBC. Note: *CH - mainland China.



Daily cases continue to

Malavsia

moderate in Indonesia and

COVID-19 in Asia

Chart 7: Indonesia



Source: CEIC, HSBC

Chart 8: Malaysia



Source: CEIC, HSBC

Chart 9: Philippines





Source: CEIC, HSBC

Chart 11: Thailand



Source: CEIC, HSBC

Chart 10: Singapore



Chart 12: Vietnam

Confirmed cases Vietnam Daily change 900,000 19,200 800,000 16,000 700,000 600,000 12,800 500.000 9,600 400,000 300,000 6,400 200,000 3,200 100,000 ٥ 0 Feb-20 Jun-20 Oct-20 Feb-21 Jun-21 Daily change (RHS) ----- Number of confirmed cases

Source: CEIC, HSBC

Thailand's news cases stabilised; Vietnam's new cases have dropped





The Delta outbreak has been largely contained in mainland

China; while new cases

New cases continue to

a small flare-up in cases

remain elevated in Australia;

while New Zealand has seen

stabilised in India

COVID-19 in Asia

Chart 13: Mainland China



Chart 14: India



Source: CEIC, HSBC

Chart 15: Australia

Source: CEIC, HSBC



Source: CEIC, HSBC

Chart 16: New Zealand



Source: CEIC, HSBC

Chart 18: South Korea



Source: CEIC, HSBC

New cases have dropped below 1k in Japan and have moderated in South Korea

Chart 17: Japan



Source: CEIC, HSBC



Vaccine Data and Timelines

Chart 19: Potential vaccine coverage by population (confirmed doses + doses under negotiation)



Potential vaccine coverage not yet 100% of population for few Asian economies

A large portion of Vietnam's

and is still under negotiation

total vaccine commitment

has not yet been finalised

Most economies in Asia

could reach 70% vaccination

rates by 1H22e, but it may take longer for ASEAN

Source: Duke University Health Innovation Center, HSBC

Chart 20: Share of confirmed vaccine dose purchases vs doses still under negotiations



Note: China* – mainland China. Source: Duke University Health Innovation Center, HSBC



Chart 21: Vaccination timelines to reach 70% vaccination rate (analyst estimates)

Note: *CH – mainland China. Source: HSBC projections extrapolated from current rates of vaccination and vaccine supply.



ASEAN COVID-19 Trends

Chart 22: Daily new COVID-19 cases



Source: CEIC, HSBC

Chart 23: Oxford Stringency Index time series

Government containment measures persist across ASEAN



Source: CEIC, HSBC





Daily fatalities have dropped across ASEAN

Source: CEIC, HSBC





Economic Indicators



Ground traffic in key ASEAN cities has improved gradually

in many ASEAN cities





Chart 26: Air traffic trends across Asia



Source: Flight Tracker, HSBC





Government stringency measures have seen a notable drop in Sri Lanka and Vietnam

Note: *CH - mainland China. Source: CEIC, HSBC



Economic Indicators



Chart 28: Average non-residential mobility (recent vs one month ago)

Note: Comparison to Google baseline. The baseline is the median value, for the corresponding day of the week, during the five-week period of 3 January 2020-6 February 2020. Source: CEIC, HSBC



Chart 29: Mobility data: Average non-residential COVID-19 tracker

Note: Comparison to Google baseline. The baseline is the median value, for the corresponding day of the week, during the five-week period of 3 January 2020-6 February 2020. Source: CEIC, HSBC



Disclosure appendix

Analyst Certification

The following analyst(s), economist(s), or strategist(s) who is(are) primarily responsible for this report, including any analyst(s) whose name(s) appear(s) as author of an individual section or sections of the report and any analyst(s) named as the covering analyst(s) of a subsidiary company in a sum-of-the-parts valuation certifies(y) that the opinion(s) on the subject security(ies) or issuer(s), any views or forecasts expressed in the section(s) of which such individual(s) is(are) named as author(s), and any other views or forecasts expressed herein, including any views expressed on the back page of the research report, accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Yun Liu, Frederic Neumann and Heidi Tang

Important disclosures

This document has been prepared and is being distributed by the Research Department of HSBC and is not for publication to other persons, whether through the press or by other means.

This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy the securities or other investment products mentioned in it and/or to participate in any trading strategy. Advice in this document is general and should not be construed as personal advice, given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. If necessary, seek professional investment and tax advice.

Certain investment products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. Investors should consult with their HSBC representative regarding the suitability of the investment products mentioned in this document and take into account their specific investment objectives, financial situation or particular needs before making a commitment to purchase investment products.

The value of and the income produced by the investment products mentioned in this document may fluctuate, so that an investor may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Value and income from investment products may be adversely affected by exchange rates, interest rates, or other factors. Past performance of a particular investment product is not indicative of future results.

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at www.hsbcnet.com/research. HSBC Private Banking clients should contact their Relationship Manager for queries regarding other research reports. In order to find out more about the proprietary models used to produce this report, please contact the authoring analyst.

Additional disclosures

- 1 This report is dated as at 15 October 2021.
- 2 All market data included in this report are dated as at close 14 October 2021, unless a different date and/or a specific time of day is indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.
- 4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.



Disclaimer

Legal entities as at 1 December 2020

¹UAE' HSBC Bank Middle East Limited, DIFC; HSBC Bank Middle East Limited, Dubai; ¹HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; ¹TW' HSBC Securities (Taiwan) Corporation Limited; ¹CA' HSBC Securities (Canada) Inc.; ¹France' HSBC Continental Europe; ¹Spain' HSBC Continental Europe, Sucursal en España; ¹Italy' HSBC Continental Europe, Italy; ¹Sweden' HSBC Continental Europe Bank, Sweden Filial; ¹DE' HSBC Trinkaus & Burkhardt AG, Düsseldorf; 000 HSBC Bank (RR), Moscow; ¹IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; ¹JP' HSBC Securities (Japan) Limited, Tokyo; ¹EG' HSBC Securities Egypt SAE, Cairo; ¹CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Securities (South Africa) (Pty) Ltd, Johannesburg; HSBC Bank plc, London, Tel Aviv; ¹US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation HSBC; HSBC Bank Australia Limited; HSBC Ganta Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation HSBC; HSBC Bank HSBC Indonesia; HSBC Qianhai Securities Limited; Banco HSBC SA.

Issuer of report The Hongkong and Shanghai Banking Corporation Limited Level 19, 1 Queen's Road Central Hong Kong SAR Telephone: +852 2843 9111 Fax: +852 2801 4138 Website: www.research.hsbc.com

The Hongkong and Shanghai Banking Corporation Limited ("HSBC") has issued this research material. The Hongkong and Shanghai Banking Corporation Limited is regulated by the Hong Kong Monetary Authority. If it is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. In the UK, this publication is distributed by HSBC Bank plc for the information of its Clients (as defined in the Rules of FCA) and those of its affiliates only. Nothing herein excludes or restricts any duty or liability to a customer which HSBC Bank plc has under the Financial Services and Markets Act 2000 or under the Rules of FCA and PRA. A recipient who chooses to deal with any person who is not a representative of HSBC Bank plc in the UK will not enjoy the protections afforded by the UK regulatory regime. HSBC Bank plc is regulated by the Financial Conduct Authority and the Prudential Regulation Authority. In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (ABN 48 006 434 162, AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. This publication is distributed in New Zealand by The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR.

In the European Economic Area, this publication has been distributed by HSBC Continental Europe or by such other HSBC affiliate from which the recipient receives relevant services This material is distributed in Japan by HSBC Securities (Japan) Limited. HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. The information contained herein is under no circumstances to be construed as investment advice and is not tailored to the needs of the recipient. All US persons receiving and/or accessing this report and intending to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report. In Korea, this publication is distributed by either The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") or The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch ("HBAP SEL") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. Both HBAP SLS and HBAP SEL are regulated by the Financial Services Commission and the Financial Supervisory Service of Korea. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. Only Economics or Currencies reports are intended for distribution to a person who is not an Accredited Investor, Expert Investor or Institutional Investor as defined in SFA. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch accepts legal responsibility for the contents of reports pursuant to Regulation 32C(1)(d) of the Financial Advisers Regulations. This publication is not a prospectus as defined in the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. Please refer to The Hongkong and Shanghai Banking Corporation Limited Singapore Branch's website at www.business.hsbc.com.sg for contact details. HSBC México, S.A., Institución de Banca Múltiple, Grupo Financiero HSBC is authorized and regulated by Secretaría de Hacienda y Crédito Público and Comisión Nacional Bancaria y de Valores (CNBV).

In Canada, this document has been distributed by HSBC Securities (Canada) Inc. (member IIROC), and/or its affiliates. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offense. In Brazil, this document has been distributed by Banco HSBC S.A. ("HSBC Brazil"), and/or its affiliates. As required by Instruction No. 598/18 of the Securities and Exchange Commission of Brazil (Comissão de Valores Mobiliários), potential conflicts of interest concerning (i) HSBC Brazil and/or its affiliates; and (ii) the analyst(s) responsible for authoring this report are stated on the chart above labelled "HSBC & Analyst Disclosures".

Any recommendations contained in it are intended for the professional investors to whom it is distributed. This material is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of HSBC only and are subject to change without notice. From time to time research analysts conduct site visits of covered issuers. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits. The decision and responsibility on whether or not to invest must be taken by the reader. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of any companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform banking or underwriting services for or relating to those companies. This material may not be further distributed in whole or in part for any purpose. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. (070905) If you are an HSBC Private Banking ("PB") customer with approval for receipt of relevant research publications for accessing research and the terms and conditions of any other internet banking service offered by that HSBC entity through which you will access research publications ("the Terms"). Distribution

© Copyright 2021, The Hongkong and Shanghai Banking Corporation Limited, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of The Hongkong and Shanghai Banking Corporation Limited. MCI (P) 028/02/2021, MCI (P) 087/10/2020

[1180157]